Table 1.
The role of ferroptosis in fibrosis.
| Organ | Mechanism | Molecular foundation | Ref |
|---|---|---|---|
| Liver | Iron overload-induced toxicity | Iron distribution disorder: iron in hepatocytes is excreted into adjacent HSCs through extracellular vesicles. | [46] |
| Iron overload promotes ferroptosis in hepatocytes by inducing HO-1 overexpression. | [55] | ||
| Trf-TFR1 mediates iron accumulation and causes ferroptosis in hepatocytes. | [57] | ||
| Zip14-mediated accumulation of NTBI causes ferroptosis in hepatocytes with a Trf deficiency. | [57] | ||
| Hepatic stellate cell activation | The RNA-binding protein ELAVL1/HuR induces HSC ferroptosis by regulating the autophagy pathway. | [58] | |
| The RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating the autophagy signaling pathway in HSCs. | [86] | ||
| Artemether ameliorates liver fibrosis by inhibiting HSC activation via p53-dependent ferroptosis. | [60] | ||
| Artesunate ameliorates hepatic fibrosis by mediating HSC ferritinophagy. | [64] | ||
| Magnesium isoglycyrrhizinate ameliorates hepatic fibrosis by inhibiting HSC activation via HO-1-mediated ferroptosis. | [65] | ||
| Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via the HIF-1α/SLC7A11 pathway. | [120] | ||
| Wogonoside alleviates liver fibrosis by inducing SOCS1/P53/SLC7A11-mediated HSC ferroptosis. | [122] | ||
| The BRD7-P53-SLC25A28 axis plays an important role in the ferroptosis of HSCs. | [67] | ||
| Activation of inflammation | Ferroptotic cells release DAMPs to exacerbate tissue inflammation and fibrosis. | [44] | |
| Lung | Fibroblast-to-myofibroblast differentiation | GPX4 inhibits and upregulates TGF-β signaling to promote pulmonary fibrosis. | [76] |
| Erastin promotes fibroblast-to-myofibroblast differentiation by increasing lipid peroxidation and inhibiting GPX4 expression. | [77] | ||
| Oxidative damage | Liproxstatin-1 activates the Nrf2 pathway by weakening TGF-β expression to attenuate RILF. | [81] | |
| DHQ exerts antifibrotic effects by inhibiting ferroptosis through the downregulation of LC3 and upregulation of FTH1 and NCOA4 in activated HBE cells. | [101] | ||
| Activation of inflammation | Accumulating inflammatory macrophages induce AT2 cell ferroptosis via the ALOX5-LTB4-ACSL4 axis. | [91] | |
| Kidney | Activation of inflammation | Ferroptotic cells release profibrotic factors (TGF-β, CTGF, and PDGF). | [105] |
| Accumulation of proinflammatory PT cells significantly downregulates GSH to increase inflammation and fibrosis. | [106] | ||
| Tectorigenin alleviates fibrosis by inhibiting ferroptosis in TECs through the Smad3-NOX4 pathway. | [46] | ||
| Heart | Oxidative damage | MLK3-JNK/p53 pathway-mediated oxidative stress and ferroptosis cause myocardial fibrosis. | [111] |
| Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling. | [113] | ||
| Elabela antagonizes ferroptosis by regulating the IL-6/STAT3/GPX4 signaling pathway to prevent adverse myocardial remodeling. | [112] | ||
| Submandibular gland | Activation of inflammation | Ferroptotic cells accelerate salivary gland fibrosis by secreting IL-1 and TNF-α. | [118] |